7 Review of guidance
7.1 The guidance on this technology will be considered for review, together with NICE technology appraisal guidance 259 (Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen), in April 2015. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.
Andrew Dillon
Chief Executive
July 2014